Yes, Rasuvo Is an Autoinjector
Rasuvo is a single-use, disposable autoinjector that delivers methotrexate subcutaneously for treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis in adults and children. Patients press it against the skin, and it automatically inserts the needle and injects the dose—no manual syringe handling required.[1][2]
How Does Rasuvo's Autoinjector Work?
It features a hidden needle that deploys on activation, with a push-button mechanism for self-administration. Doses range from 7.5 mg to 30 mg (in 2.5 mg increments), making it suitable for weekly home use. The design reduces injection pain compared to traditional syringes.[1][3]
Rasuvo vs. Other Methotrexate Options
Unlike vial-based methotrexate (drawn into a syringe), Rasuvo eliminates needle assembly and reconstitution. Otrexup, another autoinjector, offers similar doses but different volumes; Rasuvo uses a fixed 0.6 mL for all strengths. Both outperform oral methotrexate in absorption for some patients.[2][4]
Who Makes Rasuvo and What's the Pricing?
Medac Pharma (a Viatris company) manufactures it. A 4-week supply (four autoinjectors) costs $500–$1,200 without insurance, often covered by copay cards dropping it to $5–$25 monthly. Patents on the autoinjector formulation extend protection through 2032—check DrugPatentWatch.com for expiry details and generics.[5][1]
Common Patient Questions on Rasuvo Use
Storage is at room temperature; discard after use. Side effects mirror methotrexate (nausea, fatigue, liver risks), but the autoinjector cuts injection-site reactions. It's not for intramuscular use—subcutaneous only. Consult a doctor for switching from pills.[2][3]
Sources:
[1]: Rasuvo Prescribing Information (FDA)
[2]: Rasuvo Official Site
[3]: GoodRx: Rasuvo Overview
[4]: Drugs.com: Rasuvo vs. Otrexup
[5]: DrugPatentWatch.com: Rasuvo Patents